27 June 2023
Humanized liver mouse models translation of antivirals for HBV and HDV
Generating high-quality, pre-clinical data is always challenging, but it is especially so when developing therapeutics for hepatitis B and D. Since Hepatitis B Virus (HBV) and Hepatitis D Virus (HDV) only infect human hepatocytes, conventional animal models instantly pose a challenge as the entire viral lifecycle cannot be observed, and the data often doesn’t translate well to the human environment. These issues can lead to misleading metabolism, pharmacokinetics, efficacy and hepatotoxicity data, which can result in wasted time, money and resources and, potentially, failure at clinical trial stages.
